Over the past 30 years, antiretroviral drug regimens for treating HIV infection 
have become more effective, safer, and more convenient. Despite 31 currently 
approved drugs, the pipeline of investigational HIV drugs remains full. 
Investigational antiretroviral drugs include the nucleoside analogue reverse 
transcriptase translocation inhibitor (NRTTI) MK-8591, a long-acting compound 
that could be dosed once weekly. Investigational nonnucleoside analogue reverse 
transcriptase inhibitors (NNRTIs) include doravirine, which is active in vitro 
against NNRTI-resistant HIV and was potent and well-tolerated when used in 
combination with a dual-nucleoside analogue RTI (nRTI) backbone in 
treatment-naive individuals.New integrase strand transfer inhibitors (InSTIs) 
include recently approved bictegravir, which is active against InSTI-resistant 
viral strains in vitro and was potent and well-tolerated in combination regimens 
in treatment-naive individuals, and investigational cabotegravir, which is being 
studied with monthly parenteral dosing for HIV maintenance treatment and with 
bimonthly dosing for HIV preexposure prophylaxis (PrEP). Investigational HIV 
entry inhibitors include the new CD4 attachment inhibitor fostemsavir, which 
targets HIV envelope glycoprotein 120, and recently approved ibalizumab, which 
binds the CD4 receptor. This article summarizes presentations by Roy M. Gulick, 
MD, MPH, at the IAS-USA continuing education program, Improving the Management 
of HIV Disease, held in Los Angeles, California, in April 2017, and at the 2017 
Ryan White HIV/AIDS Program Clinical Conference, held in San Antonio, Texas, in 
August 2017.